Use of Apixaban in Patients with Neurodegenerative Conditions

Introduction to Apixaban Use

The American College of Cardiology recommends apixaban can be used in patients with Kennedy disease with appropriate dose adjustments based on renal function, as there are no specific contraindications for its use in this neurodegenerative condition 1, 2

Renal function is the primary determinant for Eliquis (apixaban) dosing, not the presence of Kennedy disease itself, according to the American College of Chest Physicians and the Journal of the American College of Cardiology 3, 4
Standard dosing recommendations based on renal function should be followed when prescribing apixaban, as suggested by the American Heart Association 5
Apixaban has more predictable pharmacological profiles and fewer drug-drug interactions compared to warfarin, making it potentially advantageous in patients with chronic conditions, as noted by the American College of Cardiology 6

For patients with normal or mild renal impairment, the recommended dose is 5 mg twice daily (or 2.5 mg twice daily if two of the following are present: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL), as recommended by the American College of Cardiology 1, 2
For patients with moderate renal impairment (CrCl 30-50 mL/min), the recommended dose is 5 mg twice daily (or 2.5 mg twice daily with the same criteria as above), according to the American College of Cardiology and the Journal of the American College of Cardiology 1, 7
For patients with severe renal impairment (CrCl 15-30 mL/min), a dose of 2.5 mg twice daily is recommended by some guidelines, though official recommendations vary, as noted by the American College of Chest Physicians and the Journal of the American College of Cardiology 3, 7
For patients with end-stage renal disease (CrCl <15 mL/min or dialysis), limited data suggests a dose of 5 mg BID with reduction to 2.5 mg BID if age ≥80 years or weight ≤60 kg, as recommended by the Journal of the American College of Cardiology 4, 7

Apixaban is associated with a lower risk of intracranial bleeding compared to warfarin, which is particularly important in neurodegenerative conditions, as noted by the American College of Cardiology 6
Apixaban does not require regular INR monitoring, which can improve quality of life in patients with chronic conditions, according to the American College of Cardiology 6

Renal function should be evaluated before initiation of apixaban and reassessed at least annually and when clinically indicated, as recommended by the American Heart Association and the European Society of Cardiology 1, 8
For impaired renal function (CrCl ≤60 mL/min), more frequent evaluation is recommended, as suggested by the European Society of Cardiology 8
Patients should be monitored for signs of bleeding, especially if they have additional risk factors, as noted by the National Comprehensive Cancer Network 9

Concomitant use of dual P-glycoprotein and strong CYP3A4 inducers or inhibitors should be done with caution, particularly in the setting of chronic kidney disease, as recommended by the American Heart Association and the European Society of Cardiology 1, 8
Apixaban may require dose adjustment or avoidance with certain medications that affect these pathways, as noted by the American College of Cardiology 5